Yellow Fever Virus Genotyping Tool Using RT-qPCR Followed by Nucleotide Sequencing and Phylogenetic Analysis.

Izabela M Rezende, Lívia Sacchetto, Pedro A Alves, A Desiree Labeaud, Betânia P Drumond

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Izabela M RezendeDepartment of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA, USA. irezende@stanford.edu.

Lívia SacchettoDepartment of Dermatological, Infectious and Parasitic Diseases, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil.

Pedro A AlvesLaboratory of Immunology and Viral Diseases, René Rachou Institute (Fiocruz Minas), Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.

A Desiree LabeaudDepartment of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA, USA.

Betânia P DrumondLaboratory of Viruses, Department of Microbiology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil. betaniadrumond@ufmg.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yellow fever is an infectious disease preventable by vaccination. The vaccine is composed of a live attenuated virus that, in some cases, may lead to adverse events, as neurological or viscerotropic disease. The differentiation between serious adverse vaccine events and natural infection by yellow fever virus is essential, especially in yellow fever endemic areas. Here we describe a genotyping tool to distinguish the vaccine from wild-type viruses. Experimental assays confirmed the discrimination between South American I and vaccine viruses, but in silico analyses also show its potential to be used for the differentiation of all yellow fever virus genotypes.

Indexed as

Genotyping TechniquesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionSequence Analysis, DNAYellow fever virusGenotypeHumansPhylogenyRNA, ViralYellow FeverYellow Fever VaccineRNA, ViralYellow Fever VaccineAdverse vaccination eventGenotyping toolImmunizationNS5 genePhylogenetic analysisRT-qPCRSequencingVaccinationVaccineYellow feverYellow fever virus

Identifiers

PMID40249432

DOI10.1093/sysbio/42.2.182

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.